Malignant neoplasm of isthmus uteri
ICD-10 C54.0 is a billable code used to indicate a diagnosis of malignant neoplasm of isthmus uteri.
C54.0 refers to a malignant neoplasm located at the isthmus of the uterus, which is the narrow region connecting the cervix to the body of the uterus. This type of cancer is classified under gynecologic malignancies and can present with various symptoms, including abnormal vaginal bleeding, pelvic pain, and changes in menstrual patterns. The diagnosis is typically confirmed through histopathological examination following a biopsy. Staging of the cancer is crucial for determining the extent of disease and guiding treatment options, which may include surgery, radiation therapy, and chemotherapy. The CA-125 blood test may be utilized as a tumor marker, particularly in monitoring treatment response and recurrence, although it is not specific to uterine cancers. Surgical approaches often involve hysterectomy, which may be total or radical, depending on the stage and spread of the malignancy. Accurate coding for C54.0 is essential for appropriate treatment planning and reimbursement.
Detailed pathology reports, imaging studies, and surgical notes.
Diagnosis and treatment planning for uterine cancers, including staging and follow-up care.
Ensure accurate documentation of tumor size, grade, and staging to support coding.
Imaging reports that detail findings related to the isthmus and surrounding structures.
Preoperative imaging for surgical planning and post-treatment surveillance.
Radiologists should clearly document any findings that may indicate malignancy.
Performed for treatment of malignant neoplasm of isthmus uteri.
Operative report detailing the procedure and findings.
Ensure that the surgical approach and findings are clearly documented.
CA-125 is a tumor marker that can help in monitoring treatment response and recurrence in patients with malignant neoplasms of the uterus, including C54.0. However, it is not specific to uterine cancer and should be interpreted in conjunction with other clinical findings.
